Literature DB >> 1008609

Connective tissue metabolism in culture fibroblasts of a patient with Ehlers-Danlos syndrome type I.

H Shinkai, O Hirabayashi, A Tamaki, S Matsubayashi, S Sano.   

Abstract

Study on connective tissue metabolism was conducted with a patient with Ehlers-Danlos syndrome (E-D) of Type I who visited our institute. The conversion of procollagen into tropocollagen in the medium of cultured fibroblasts was assayed by the chase technique using 3H-proline. The conversion was inhibited in the cultured fibroblasts of the patient. The components of glycosaminoglycans in cultured medium and fibroblasts from E-D were within normal ranges, however, the ratio of glycoprotein to glycosaminoglycans of intra- and extra-cellular fractions of E-D fibroblasts was higher than the normal one. These findings suggest that the insufficient maturation of collagen fiber may be considered fundamental disorders of E-D.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1008609     DOI: 10.1007/bf00558084

Source DB:  PubMed          Journal:  Arch Dermatol Res            Impact factor:   3.017


  11 in total

1.  Lysyl oxidase deficiency in Ehlers-Danlos syndrome type V.

Authors:  N Di Ferrante; R D Leachman; P Angelini; P V Donnelly; G Francis; A Almazan
Journal:  Connect Tissue Res       Date:  1975       Impact factor: 3.417

2.  Interaction of tropocollagen with protein-polysaccharide complexes. An analysis of the ionic groups responsible for interaction.

Authors:  V Podrazky; F S Steven; D S Jackson; J B Weiss; S J Leibovich
Journal:  Biochim Biophys Acta       Date:  1971-03-23

3.  Defect in conversion of procollagen to collagen in a form of Ehlers-Danlos syndrome.

Authors:  J R Lichtenstein; G R Martin; L D Kohn; P H Byers; V A McKusick
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

4.  Acidic structural proteins of connective tissue. I. Solubilization and preliminary chemical characterization.

Authors:  R Timpl; I Wolff; M Weiser
Journal:  Biochim Biophys Acta       Date:  1969-11-11

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Evidence for procollagen, a biosynthetic precursors of collagen.

Authors:  G Bellamy; P Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

7.  Lysyl-protocollagen hydroxylase deficiency in fibroblasts from siblings with hydroxylysine-deficient collagen.

Authors:  S M Krane; S R Pinnell; R W Erbe
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

8.  Hydroxylysine-deficient skin collagen in a patient with a form of the Ehlers-Danlos syndrome.

Authors:  M Sussman; J R Lichtenstein; T P Nigra; G R Martin; V A McKusick
Journal:  J Bone Joint Surg Am       Date:  1974-09       Impact factor: 5.284

9.  Procollagen peptidase: an enzyme excising the coordination peptides of procollagen.

Authors:  C M Lapière; A Lenaers; L D Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

10.  Patients with Ehlers-Danlos syndrome type IV lack type III collagen.

Authors:  F M Pope; G R Martin; J R Lichtenstein; R Penttinen; B Gerson; D W Rowe; V A McKusick
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  3 in total

Review 1.  Diseases of the collagen molecule.

Authors:  C I Levene
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

2.  Exclusion of COL1A1, COL1A2, and COL3A1 genes as candidate genes for Ehlers-Danlos syndrome type I in one large family.

Authors:  B P Sokolov; A N Prytkov; G Tromp; R G Knowlton; D J Prockop
Journal:  Hum Genet       Date:  1991-12       Impact factor: 4.132

3.  [Ehlers-Danolos syndrome: a disease of fibroblasts and collagen fibrils. Classification and electron-microscopic findings in five patients (author's transl)].

Authors:  M Sevenich; U Schultz-Ehrenburg; C E Orfanos
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.